Entero Therapeutics (NASDAQ:GRDX) Releases Earnings Results

Entero Therapeutics (NASDAQ:GRDX) posted its earnings results on Friday. The company reported ($1.88) earnings per share for the quarter, FiscalAI reports.

Entero Therapeutics Stock Up 0.4%

NASDAQ GRDX opened at $2.52 on Friday. The firm has a market capitalization of $8.47 million, a P/E ratio of -1.49 and a beta of 1.38. Entero Therapeutics has a twelve month low of $1.01 and a twelve month high of $5.84. The firm has a fifty day moving average of $2.28.

Institutional Trading of Entero Therapeutics

An institutional investor recently bought a new position in Entero Therapeutics stock. DRW Securities LLC purchased a new stake in Entero Therapeutics, Inc. (NASDAQ:GRDX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned approximately 1.45% of Entero Therapeutics at the end of the most recent quarter. 12.30% of the stock is owned by institutional investors and hedge funds.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.